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Renal insufficiency increases cardiovascular risk, accelerates
atherogenesis, and causes vascular wall remodeling. Here we
evaluated the effect of the calcimimetic R-568 and non-
hypercalcemic doses of calcitriol on vascular structure.
Subtotal nephrectomy was produced in Sprague-Dawley rats
followed by treatment with R-568, calcitriol, or vehicle for 12
weeks. The aortic wall was significantly thicker in vehicle-
treated uremic rats than in those with a sham-operation but
R-568-treated uremic rats had a lower value. In contrast,
calcitriol increased wall thickness in both the sham-operated
and uremic groups. The calcification score, measured by von
Kossa staining, and the number of proliferating cells in the
intima and media were significantly higher in the calcitriol-
treated uremic group. The expression of the calcium sensing
receptor was higher in the intima of sham-operated and
uremic rats treated with R-568 compared to animals treated
with vehicle or calcitriol, while the expression of the vitamin
D receptor was upregulated by both calcitriol and R-568. Our
study shows that in uremic rats, calcitriol increased while
R-568 attenuated media calcification and proliferation of
vascular smooth muscle and endothelial cells.
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Coronary artery disease and myocardial infarction are known
causes of death in patients with chronic kidney disease.1
Atherogenesis is accelerated in patients with chronic kidney
disease2 and in uremic animals.3,4 In addition to accelerated
atherogenesis, chronic kidney disease also increases vascular
stiffness, further increasing cardiovascular (CV) risk.
In primary hyperparathyroidism, CV morbidity and
mortality are increased,5 and this is associated with an
adverse CV risk profile.6 High serum parathyroid hormone
(PTH) concentrations are associated with increased CV risk,
even in the absence of further CV risk factors.7 Whether high
PTH also makes an independent contribution to the elevated
CV risk in secondary hyperparathyroidism has not been
resolved. Clinical studies are limited because most of the
available treatment options (calcium-containing phosphate
binders, vitamin D) can cause an increase in calcemia
(especially at high doses) thus promoting calcification of
vessel walls.8 On the other hand, however, physiologic
vitamin D concentrations are essential for optimal vascular
function.9 Observational studies suggest that CV mortality is
lower in vitamin D-treated patients10 but prospective
controlled evidence is not available.11
The recent introduction of calcimimetics, small organic
molecules that allosterically modulate the calcium-sensing
receptor (CaSR), provides the opportunity to lower PTH
levels without raising blood calcium and phosphorus
concentrations.
The CaSR is expressed in vascular endothelial and smooth
muscle cells,12–14 and its activation affects vascular tone.15–17
It is not known, however, whether treatment with calci-
mimetics affects structural remodeling of the vessel wall.
Against this background, it was the aim of this study to
study vascular remodeling of large vessels and to compare the
effects of long-term treatment with a calcimimetic (R-568)
and with calcitriol in subtotally nephrectomized rats.
RESULTS
Animal data
Serum creatinine was significantly increased in all subtotally
nephrectomized (SNX) groups and was not changed by the
treatments (Table 1). Total and high-density lipoprotein
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(HDL) serum cholesterol were significantly higher in
sham-opþ calcitriol compared with sham-opþ vehicle and
sham-opþR-568. Total, HDL and low-density lipoprotein
cholesterol were significantly higher in SNX compared with
sham-op irrespective of the treatment (Table 1).
The serum calcium concentration was not significantly
changed in any group. The phosphorus concentration was
significantly higher in the SNXþ vehicle and SNXþ calcitriol
compared with sham-op animals; in SNXþR-568 it was
significantly lower than in SNXþ vehicle. Serum PTH
concentration was significantly higher in SNXþ vehicle, but
not in the SNXþR-568 or SNXþ calcitriol groups compared
with sham-op rats (Table 1).
Albumin excretion at week 12 was significantly lower in
SNXþR-568 and SNXþ calcitriol groups compared with
SNXþ vehicle, but higher compared with sham-operated
animals (Table 1).
Systolic blood pressure at week 12 was significantly higher
in SNX compared with sham-op rats irrespective of the
treatment (Table 1).
Vascular morphology
The thickness of the aortic intima was significantly higher in
sham-opþ calcitriol compared with other sham-op groups
(Figure 1). The thickness of the aortic intima in SNXþ calci-
triol was also significantly higher than in the SNXþ vehicle
or SNXþR-568 groups. The same was true for media
thickness.
Significantly more calcium deposits, that is Kossa-positive
areas (Figure 2), were observed in the media (but not intima)
Table 1 | Animal data
Group
Systolic blood
pressure at
week 12
(mm Hg)
Albumin
excretion at
week 12
(mg/24 h)
Serum
creatinine
(mg/100 ml)
Serum
cholesterol
(mg/100 ml)
Serum HDL-
cholesterol
(mg/100 ml)
Serum LDL-
cholesterol
(mg/100 ml)
Serum
calcium
(mmol/l)
Serum
phosphorus
(mmol/l)
Serum PTH
(pg/ml)
Sham-op+vehicle
(n=16)
125±23 0.4±0.2 0.55±0.09 69±25 43±15 17±12 2.64±0.18 2.28±0.31 111±37
Sham-op+R-568
(n=15)
135±17 0.6±0.4 0.50±0.06 58±12 37±7 14±4 2.56±0.21 2.41±0.22 64±27
Sham-op+calcitriol
(n=20)
125±12 0.8±0.4 0.61±0.08 94±19a,b 52±12b 16±6 2.78±0.15 2.21±0.28 93±12
SNX+vehicle (n=17) 168±20a,b,c 39.0±24.8a,b,c 1.05±0.36a,b,c 109±39a,b 61±24a,b 31±18a,b,c 2.66±0.25 2.78±0.56a,b,c 475±263a,b,c
SNX+R-568 (n=20) 169±12a,b,c 17.9±12.7a,b,c,d 1.16±0.32a,b,c 104±33a,b 69±26a,b 26±17b 2.68±0.22 2.46±0.29d 147±105d
SNX+calcitriol (n=17) 158±21a,b,c 16.6±10.7a,b,c,d 1.09±0.30a,b,c 123±56a,b,c 62±11a,b 31±21a,b,c 2.73±0.13 2.66±0.37a,c 182±121d
ANOVA Po0.001 Po0.001 Po0.001 Po0.001 Po0.001 P=0.004 NS Po0.001 Po0.001
ANOVA, analysis of variance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant; SNX, subtotally nephrectomized.
All values presented as mean±s.d.
aPo0.05 vs sham+vehicle.
bPo0.05 vs sham+R-568.
cPo0.05 vs sham+calcitriol.
dPo0.05 vs SNX+vehicle.
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Figure 1 | Hystology of the aorta. Thickness of aortic (a) intima and (b) media. aPo0.05 vs shamþ vehicle; bPo0.05 vs shamþ R-568;
cPo0.05 vs shamþ calcitriol; dPo0.05 vs SNXþ vehicle; ePo0.05 vs SNXþ R-568.
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of SNXþ vehicle compared to sham-opþ vehicle rats. This
finding was less pronounced after treatment with R-568 but
more pronounced after treatment with calcitriol.
Calcium-sensing receptor and vitamin D receptor
The immune staining for the CaSR in the intima and media
of the aorta and in intramyocardial arteries was not
significantly different in uremic vs nonuremic vehicle-treated
animals. Treatment with R-568, but not with calcitriol,
caused significantly more immune staining for the CaSR in
both intima and media of the aorta in SNX as well as sham-
op animals (Figure 3a and b). The staining for the CaSR was
especially marked in areas surrounding loci of calcification
(Figure 3g-i inserts).
The results were confirmed by Western blot analysis of
aortic tissue (Figure 3c) and by mRNA in situ hybridization.
Similar CaSR expression (immune staining and mRNA in situ
hybridization) was found in muscular, for example intra-
myocardial (Figure 4) and intrarenal arteries (data not
shown).
Endothelial staining for vitamin D receptor (VDR) was
significantly lower in the intima of the aorta and the
intrarenal muscular arteries of vehicle-treated SNX (score
0.23±0.08 and 0.02±0.04 in aorta and intrarenal arteries,
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Figure 2 | Calcium deposits in the media of the aorta. aPo0.05
vs shamþ vehicle; bPo0.05 vs shamþ R-568; cPo0.05 vs shamþ
calcitriol; dPo0.05 vs SNXþ vehicle; ePo0.05 vs SNXþ R-568.
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Figure 3 | Hystology of the aorta. Expression of calcium-sensing receptor (CaSR) in aortic (a) intima and (b) media by
immunohistochemistry and in aortic tissue by (c) Western blot. Representative examples of immune staining of aorta from (d) sham-
opþ vehicle, (e) sham-opþ R-568, (f) sham-opþ calcitriol, (g) SNXþ vehicle, (h) SNXþ R-568, and (i) SNXþ calcitriol. Magnification  400.
Staining in calcified regions (inserts).
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respectively) compared with sham-op (0.51±0.22 and
0.39±0.33) animals. It was significantly higher in SNX rats
treated with calcitriol (0.49±0.30 and 0.49±0.35) or R-568
(0.48±0.16 and 0.52±0.45) than in vehicle-treated SNX rats
(analysis of variance P¼ 0.042 and 0.040). No difference of
staining for VDR was observed in the aortic media between
the groups. No difference in VDR expression was noticed in
western blot and mRNA in situ hybridization (data not
shown).
Markers of vascular wall remodeling
The number of proliferating cell nuclear antigen (PCNA)-
positive cells in the aortic intima and media was significantly
higher in SNXþ calcitriol compared with other groups
(Figure 5).
We found no significant difference of the immune staining
for collagen I in the media of the aorta between the study
groups (data not shown).
The immune staining for transforming growth factor-b1
(TGF-b1) was significantly more marked in the aortic intima
and media of vehicle-treated SNX compared with sham-op
animals (Table 2). This was ameliorated by the treatment
with R-568 and calcitriol. The immune-staining for TGF-b
receptor 1 (Table 2) was significantly less marked in the
intima of calcitriol- or R-568-treated sham-op rats, and
all SNX groups compared with vehicle-treated sham-op
animals. The staining for TGF-b receptor 1 in the media
of the vessel wall was significantly less in vehicle-treated
and calcitriol-treated SNX compared with vehicle treated
sham-op groups.
The staining for TGF-b receptor 2 and vascular endothe-
lial growth factor (VEGF) in intima and media was not
significantly different between the groups. The staining for
VEGF receptor type 1 (flt-1) was significantly less marked in
the intima and media of all SNX compared with sham-op
groups irrespective of the treatment (Table 2). The staining
for VEGF receptor type 2 (flk-1) was significantly more
marked in the intima of calcitriol-treated SNX and sham-op
groups compared with respective vehicle-treated animals
(Table 2). The expression of flk-1 in the media was not
significantly different between the groups.
Markers of osteoblastic phenotype
Immune-staining for core-binding factor-a1 (cbfa-1)
(Figure 6) and osteonectin (Figure 7) in the aortic wall was
significantly more marked in vehicle-treated and calcitriol-
treated SNX and calcitriol-treated sham-op rats compared
with vehicle- or R-568-treated sham-op and R-568-treated
SNX groups. Protein expression (determined by Western
blot) of cbfa-1 in whole aortic tissue was significantly higher
in SNXþ calcitriol compared with all sham-op and SNXþR-
568 animals (Figure 8a).
The protein expression of matrix Gla protein (MGP) and
osteopontin in aorta was significantly (P¼ 0.002 and 0.009,
respectively) lower in sham-op and SNX rats treated with
calcitriol compared with animals treated with R-568 and
vehicle (Figure 8b and c).
The expression of osteocalcin in the aorta was significantly
(P¼ 0.008) lower in SNX animals treated with calcitriol and
vehicle compared with sham and SNX treated with R-568
(Figure 8d).
The expression of RANKL (receptor activator for NFkB
ligand) in aorta was not significantly different between the
groups (Figure 8e).
The expression of osteoprotegerin in the aorta was
significantly (P¼ 0.001) lower and the expression of bone
morphogenic protein 2 was significantly (P¼ 0.001) higher
in sham-op rats treated with calcitriol and SNX rats treated
with vehicle and calcitriol compared with sham-op animals
treated with vehicle and R-568 and SNXþR-568 groups
(Figure 8f and g).
The expression of phosphate transporter Pit-1 was
significantly (P¼ 0.021) lower in SNX rats treated with
R-568 compared with vehicle-treated SNX and sham-op
animals (Figure 8h).
Markers of oxidative stress and endothelial dysfunction
The immune staining for nitrotyrosine and hypoxia-induci-
ble factor-1a were not significantly different between the
groups (data not shown).
Immune staining for endothelial NO synthase was more
intense in vehicle-treated SNX (score 1.24±0.20), but not in
SNX treated with R-568- (0.55±0.43) or calcitriol-
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Figure 4 | Hystology of the aorta. Expression of CaSR in intramyocardial arteries in the (a) intima and (b) media by in situ hybridization.
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(0.57±0.31), compared with sham-op (0.47±0.27, analysis
of variance Po0.001).
DISCUSSION
In this model of renal damage, treatment with the
calcimimetic agent R-568 reduced vascular remodeling as
indicated by less PCNA in vascular smooth muscle cells
(VSMCs) and less intima–media thickness. In addition less
calcification of the vascular wall was found.
In contrast, at the dose given calcitriol caused increased
wall thickening and calcification in SNX. Such nonhypercal-
cemic doses of calcitriol caused calcium deposits in the aorta
even in sham-op rats.
According to the literature, in SNX vascular calcifications
are not consistently observed, probably depending on animal
strain and intensity of nephrectomy. Most experimental
protocols reported in literature selected observation periods
between 4 and 6 weeks18,19—considerably shorter than the 12
weeks of our experiment. High phosphate diet (0.9–1.2%)
promotes calcification in the SNX model; therefore we
deliberately chose a diet with 0.8% phosphorus.
Our results demonstrate that lack of hypercalcemia during
calcitriol treatment (at least in rodents) does not protect
against vascular calcification. To the extent that rodent
findings can be extrapolated to humans it would be wise to
select calcitriol doses as low as appropriate. At very low doses
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Magnification  400.
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calcitriol may even protect against vascular calcification by
promoting calcium retention in bone.20 Of particular interest
are observations in uremic children that both high and low
1,25(OH)2D3 concentrations are associated with adverse
morphological changes in large arteries,21 although no
independent correlation between 25(OH)D3 or
1,25(OH)2D3 on one hand and calcification scores on the
other hand had been found in adults.22
Secondary hyperparathyroidism is associated with adverse
CV outcomes in patients with chronic kidney disease.23 In
uremic animals lowering PTH by parathyroidectomy has
beneficial effects on cardiac and vascular structures.24 In
humans, CV risk is lowered by parathyroidectomy.7 The
present study documents that, despite a similar decrease of
PTH, at the given doses the effects of a calcimimetic and of
active vitamin D on vascular wall remodeling are strikingly
different. In SNX animals, thickening of the arterial wall and
media calcium deposition were prevented by R-568, whereas
in calcitriol-treated SNX animals, arterial wall thickness and
calcium deposits in the media were increased compared with
untreated SNX rats.
In parallel with thickening of intima and media the
proliferation marker PCNA was also significantly increased in
the aortic intima and media of SNX rats treated with
calcitriol. A similar trend (without statistical significance)
was seen in calcitriol-treated sham-op animals. This ob-
servation is in agreement with the in vitro observation that
active vitamin D stimulates proliferation of VSMC.25 In
calcitriol-treated sham-op rats the number of PCNA-positive
cells was not significantly higher than in untreated controls.
The observation that the same dose of calcitriol caused
vascular calcification in SNX suggests that uremia is a
permissive factor for VSMC proliferation.
It has been postulated that VEGF aggravates athero-
sclerosis,26 promotes neoangiogenesis, and increases vascular
calcification.27 The expression of the VEGF receptor flk-1,
but not flt-1, was significantly higher in the intima of animals
treated with calcitriol, although expression of VEGF was not
increased.
The expression of the profibrotic cytokine TGF-b was
increased, but the expression of the TGF-b receptor 1 was
decreased after SNX. This finding may explain the lack of
increase in collagen I deposition in the aortic wall after SNX.
Increased calcification was observed not only in large
central (aorta), but also in small muscular (intramyocardial,
intrarenal) arteries. This was associated with increased
expression of osteonectin, a permissive factor for calcifica-
tion. This finding confirms clinical and experimental
observations that calcitriol promotes generalized vascular
calcification.28,29 Of note, in sham-op animals treated with
calcitriol, vascular calcification was as pronounced as in
untreated SNX animals, despite no difference in fasting
serum calcium, phosphorus or Ca P values compared with
untreated sham-op animals. This finding supports the
hypothesis of a direct calcification-promoting action of
nonhypercalcemic doses of calcitriol on vascular smooth
muscle cells.30,31 Our observation of increased expression of
cbfa-1, a marker of an osteoblastic phenotype, in the aorta of
calcitriol-treated animals is in line with the postulated
osteoblastic transdifferentiation of VSMC.32 In the study of
Mizobuchi et al.19 clear upregulation of cbfa-1 and
osteocalcin was seen in the aorta of uremic control rats after
no more than 4 weeks—in line with our observations.
The calcimimetic did not induce vascular calcification in
uremia, and even partially prevented the calcification induced
by calcitriol treatment.28
MGP, osteoprotegerin, and osteocalcin protect against
calcification of the vascular wall33–35 and their expression was
reduced in SNX animals. MGP synthesis had been increased
by calcitriol in bone-derived cell lines.36 In contrast, in our
Table 2 | Markers of aortic wall remodeling
TGF-b1 TGF receptor 1 VEGF receptor 1 (flt-1) VEGF receptor 2 (flk-1)
Group Intima (score) Media (score) Intima (score) Media (score) Intima (score) Media (score) Intima (score) Media (score)
Sham+vehicle 1.28±0.33 1.5±0.32 1.22±0.66 1.66±0.67 3.04±1.08 2.96±0.68 0.43±0.40 1.10±0.56
Sham+R-568 0.91±0.42 1.32±0.42 0.45±0.22a 1.27±0.39 3.2±0.65 2.83±0.57 0.70±0.56 1.22±0.77
Sham+calcitriol 0.85±0.35 1.39±0.46 0.65±0.47a 1.08±0.62 2.92±0.81 2.98±0.68 1.27±0.98a,d 1.78±1.40
SNX+vehicle 1.7±1.11a,b,c 2.45±1.11a,b,c 0.37±0.43a 0.77±0.73a 1.85±0.70a,b,c 1.68±0.40a,b,c 0.38±0.15 0.55±0.48
SNX+R-568 0.73±0.45d 1.19±0.68d 0.33±0.21a 1.09±0.63 2.02±0.65a,b,c 1.66±0.69a,b,c 0.92±0.63 1.36±0.65
SNX+calcitriol 0.88±0.36d 1.36±0.68d 0.26±0.19a 0.63±0.52a 1.91±0.45a,b,c 1.88±0.44a,b,c 1.19±0.54a,d 1.48±0.88
ANOVA P=0.021 P=0.008 P=0.0003 P=0.033 P=0.003 Po0.001 P=0.029 NS
ANOVA, analysis of variance; NS, not significant; TGF-b1, transforming growth factor-b1; SNX, subtotally nephrectomized; VEGF, vascular endothelial growth factor.
All values presented as mean±s.d.
aPo0.05 vs sham+vehicle.
bPo0.05 vs sham+R-568.
cPo0.05 vs sham+calcitriol.
dPo0.05 vs SNX+vehicle.
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experiment MGP in the aorta was downregulated by calcitriol
in line with other observations in a similar model.37 The
expression was restored by the calcimimetic, but not by
calcitriol, suggesting that defence mechanisms against
calcification are mediated via the CaSR. In addition, in our
study, the expression of the calcification-promoting38 so-
dium-dependent phosphate cotransporter, Pit-1 was in-
creased in uremic animals. This effect was again prevented
by the calcimimetic.
In contrast to the findings in the aorta of a hyperlipidemic
mouse model,39 in SNX we did not observe upregulation of
osteopontin in SNX. The expression of osteopontin was
downregulated by calcitriol and this was associated with
more pronounced calcification. Osteoblastic transdifferentia-
tion of VSMC was not seen in the vascular wall of our SNX
animals treated with the calcimimetic, in line with the
observed decreased expression of calcification-promoting
proteins (bone morphogenic protein 2 and Pit-1).
CaSR is expressed in the arterial wall.13,40 Although CaSR
expression in arteries from patients with end-stage renal
disease was reported to be lower compared with healthy
controls,13 in the present model the expression of CaSR in the
vascular wall of uremic animals was not reduced. This
discrepancy may be explained by more advanced uremia in
the patients studied,13 but species differences cannot be
excluded. In this study vascular CaSR expression was
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Figure 6 | Hystology of the aorta. Immune staining for cbfa-1 in the aorta: values for (a) intima, (b) media aPo0.05 vs shamþ vehicle; bPo0.05
vs shamþ R-568; cPo0.05 vs shamþ calcitriol; dPo0.05 vs SNXþ vehicle; ePo0.05 vs SNXþ R-568; representative examples of (c) sham-opþ
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increased in uremic and nonuremic animals treated with R-
568, similar to what had been previously documented in the
parathyroid glands.41
The SNX model causes marked albuminuria.42 Our
observation of decreased albumin excretion with calcitriol
or R-568 treatment confirms previous clinical and experi-
mental findings.42–44
Although in our study total serum cholesterol levels were
higher in calcitriol-treated rats the most predominant
fraction of cholesterol in rodents is HDL cholesterol. Because
the rat is a high HDL animal this finding cannot necessarily
be extrapolated to humans.
Our observation of adverse vascular remodeling in
calcitriol-treated rats contrasts with the retrospective clinical
observations of survival benefit provided by vitamin D
treatment.10,45 The relevance of the experimental finding for
human disease is therefore unknown.
In conclusion, calcimimetics reduce arterial remodeling
and calcification in rats with subtotal nephrectomy. In
contrast, nonhypercalcemic doses of calcitriol increase
proliferation and calcification in the vessel wall. Whether
this difference will also be found in humans and will
ultimately translate into less CV events in calcimimetics-
treated uremic patients is for a matter for speculation.
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MATERIALS AND METHODS
Animals and experimental design
All animal procedures were approved by the local ethic
committee for animal experiments. Male Sprague–Dawley rats
(Charles River, Sulzfeld, Germany) aged 8 weeks, weighing
331±85 g, were housed at constant room temperature
(21±1 1C) and humidity (75±5%) and exposed to a 12 h
light-on, 12 h light-off cycle. The animals had free access to water
and a standard rodent diet (11.9 MJ/kg, 19% protein, 0.9% Ca,
0.8% P, 0.2% Na, 1.0% K, 600 IE/kg vitamin D3; Altromin, Lage-
Lippe, Germany). After a 7-day adaptation period, rats were
randomly allotted to sham operation or a two-step subtotal
(right kidney and 2/3 of the left kidney) nephrectomy (SNX)
under Isoflurane (Baxter, Unterschleissheim, Germany) anesthe-
sia and buprenorphin (0.01 mg/kg i.p.; Essex Pharma, Munich,
Germany) analgesia as previously described.46 Subsequently the
animals were randomly assigned into following study groups:
(1) Sham-op treated with vehicle (n¼ 16)
(2) Sham-op treated with R-568 (n¼ 15)
(3) Sham-op treated with calcitriol (n¼ 20)
(4) SNX treated with vehicle (n¼ 17)
(5) SNX treated with R-568 (n¼ 20)
(6) SNX treated with calcitriol (n¼ 17)
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The calcimimetic R-568 (Amgen, Thousand Oaks, CA,
USA) was dissolved in 10% 2-hydroxypropyl-b-cyclodextrin
(Sigma-Aldrich, Munich, Germany) and administered daily
(20 mg/kg body weight) subcutaneously. The dose, higher
than required to lower plasma PTH,47 was chosen following
previous reports on beneficial effects of R-568 on cardiac and
renal structure in the same model.43,46 Calcitriol (Calbio-
chem, Darmstadt, Germany) was administered daily sub-
cutaneously (30 ng/kg body weight). Control animals
received vehicle. Treatment started 4 days after surgery.
Surgery-related mortality was observed in the first 48 h
following operation and waso5% in sham-op ando10% in
SNX animals, without difference between the groups. The
animals that died after the operation were not analyzed in the
study. All animals survived the 12 weeks observation period
as originally randomized. Body weight and blood pressure
(by tail plethysmography) were measured at regular intervals
24 h after the last dose of treatment. At weeks 5 and 12
following SNX, the animals were kept in metabolic cages for
24-h urine collection.
Blood and urine analysis
The blood parameters were determined by standard labora-
tory methods in samples taken from abdominal aorta before
killing. Serum PTH was measured using a two-site rat intact
PTH (1–84) ELISA kit (Immutopics, San Clemente, CA,
USA). Urinary albumin excretion was measured using a rat-
specific ELISA kit (Bethyl, Montgomery, TX, USA).
Tissue preparation
At 12 weeks after SNX, the abdominal aorta was catheterized
under ketamine/xylazine anesthesia and the rats were killed
by retrograde pressure-controlled (120 mm Hg) perfusion
with 3% glutaraldehyde (for morphometric and stereological
investigations) or with ice-cold 0.9% NaCl (for molecular
studies). Equal number of animals were randomized for
glutaraldehyde or NaCl perfusion. Samples were prepared as
previously described.48 All samples were prepared from the
aorta proximal to the catheterization site for perfusion.
Morphology of the arteries
The media thickness of aortic walls was determined by
planimetry in eight semithin sections taken from thoracic
and abdominal aorta with a semiautomatic image analysis
system (Optimas ver. 6.0; Optimas Corp., Bothel, WA, USA
1996) at  400 magnification. For the measurement of media
thickness calcification-free samples were used. The degree of
calcification was assessed on five von Kossa-stained sections
from the aortic arch per animal. The area of calcification was
quantified using a semiautomatic image analysis system
(Optimas ver. 6.0; Optimas Corp., 1996) and expressed as %
of section stained.
Immunohistochemistry
Immunohistochemical analysis was performed on paraffin
sections using antibodies against CaSR, endothelial NO
synthase (Affinity BioReagents, Golden, CO, USA), VDR,
VEGF, TGF-b1, TGF-b receptor type 1 and type 2,
osteonectin (Santa Cruz, Heidelberg, Germany), VEGF
receptors type 1 and type 2, cbfa-1 (Abcam, Cambridge,
UK), collagen type I (Biotrend, Cologne, Germany),
nitrotyrosine, hypoxia-inducible factor-1a (Millipore,
Schwalbach, Germany), and PCNA (Immunotech, Marseilles,
France) by the streptavidin–biotin technique using alkaline
phosphatase as the labeling enzyme. All antibodies had been
tested for specificity in rats. Negative controls were
performed by omitting the primary antibody.
Immunhistologic staining was analyzed by an investigator
blinded with respect to the treatment group using a
semiquantitative scoring system (0: no expression, 1: weak,
2: moderate, 3: strong, 4: extremely strong expression). A
separate score was given for every view-field and a mean
value of all view-fields was calculated for each animal.
Intraobserver error waso5%. The number of PCNA-positive
cells was counted in two complete aortic rings at a
magnification of  400.
Western blotting
Protein samples of the entire aortas of 8–9 animals per group
were prepared by homogenization in a buffer (0.1%, Triton
X-100, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid, 4 mM EGTA, 10 mM EDTA, 15 mM Na4P2O7, 100 mM
glycerophosphate, 25 mM NaF, 1 mM sodium orthovanadate,
0.1 mM leupeptin, 50 mg/ml soy bean trypsin inhibitor, 75 mM
pepstatin A, 1 mM dithiothreitol), and centrifuged for 10 min
at 14,000 r.p.m. (þ 4 1C). Protein concentration was assessed
with the Bradford method (Protein Assay Kit; Bio-Rad
Laboratories, Munich, Germany). Equal amounts of protein
(50 mg) were electrophoresed in SDS-polyacrylamide gel
electrophoresis gel (9%) and subsequently transferred to
Immobilon-P membranes (Millipore). The membranes were
blocked with 5% nonfat dried milk for 1 h at room
temperature and then incubated with primary antibody
against CaSR (Affinity BioReagents), VDR, RANKL, osteo-
calcin, osteoprotegerin, bone morphogenic protein 2 (Santa
Cruz), cbfa-1, osteopontin (Abcam), MGP (Immuno-
diagnostic, Bensheim, Germany), or Pit-1 (Alpha Diagnos-
tics, San Antonio, TX, USA) for 2 h at room temperature.
Horseradish peroxidase-conjugated secondary antibodies
(Santa Cruz) were used, and the membrane was visualized
with the ECL kit (GE Healthcare, Buckinghamshire, UK)
according to manufacturer’s instruction. Specific bands were
quantified by densitometric analyses using a Molecular
Dynamics Personal Densitometer (EasyWin, Herolab, Ger-
many).
In situ hybridization
The expression of CaSR and VDR mRNA were evaluated
using nonradioactive in situ hybridization. For synthesis of
the CaSR RNA probe from the sequence NM016996 the
following primers were prepared—sense: 30-CGGATGAC
TTCTGGTCCAAT-50; antisense: 30-TCTTCACCAAGATG
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CACGAG-50. For synthesis of the VDR probe from the
sequence NM017058 following primers were prepared—
sense: 30-TGAAGGCTGCAAAGGTTTCT-50; antisense: 30-
TAGCTTGGGCCTCAGACTGT-50. The in situ hybridization
was performed as described previously in detail.42
The intensity of staining was assessed as described for
immunohistochemistry.
Statistics
Data are given as mean±s.d. For western blots the vehicle-
treated sham-op group served as reference and the values of
individual measurements was given as percent of the mean
value of controls. After testing for normal distribution, the
analysis of variance or Kruskal–Wallis test, as appropriate,
was chosen for analysis of variance. For the differences
between groups, Duncan’s multiple range test was used. The
results were considered significant when the P-value was
o0.05.
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